Provided by Tiger Trade Technology Pte. Ltd.

Artiva Biotherapeutics, Inc.

6.94
+0.14002.06%
Post-market: 6.940.00000.00%16:38 EDT
Volume:275.93K
Turnover:1.92M
Market Cap:339.27M
PE:-2.16
High:7.14
Open:6.84
Low:6.77
Close:6.80
52wk High:14.53
52wk Low:2.71
Shares:48.89M
Float Shares:19.09M
Volume Ratio:0.58
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2084
EPS(LYR):-3.4309
ROE:-36.58%
ROA:-22.34%
PB:0.98
PE(LYR):-2.02

Loading ...

May 08, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 08, 2026

Major Issues Report

Form 8-K - Current report
Apr 30, 2026

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Mar 10, 2026

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 10, 2026

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 10, 2026

Major Issues Report

Form 8-K - Current report
Feb 24, 2026

Major Issues Report

Form 8-K - Current report
Feb 19, 2026

Major Issues Report

Form 8-K - Current report
Dec 15, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 12, 2025

Major Issues Report

Form 8-K - Current report
Nov 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 12, 2025

Major Issues Report

Form 8-K - Current report
Nov 12, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 12, 2025

Major Issues Report

Form 8-K - Current report
Oct 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 15, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 14, 2025

Correspondence

Form CORRESP - Correspondence
Aug 06, 2025

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Aug 06, 2025

Major Issues Report

Form 8-K - Current report
Aug 06, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]